-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AZD-1390 in Fibrosarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AZD-1390 in Fibrosarcoma Drug Details: AZD-1390 is under development for the treatment of glioblastoma multiforme...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ucenprubart in Atopic Dermatitis (Atopic Eczema)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ucenprubart in Atopic Dermatitis (Atopic Eczema) Drug Details: Ucenprubart (LY-3454738) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RVT-3101 in Crohn’s Disease (Regional Enteritis)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RVT-3101 in Crohn's Disease (Regional Enteritis) Drug Details: RVT-3101 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ucenprubart in Autoimmune Disorders
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ucenprubart in Autoimmune Disorders Drug Details: Ucenprubart (LY-3454738) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AZD-1390 in Liposarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AZD-1390 in Liposarcoma Drug Details: AZD-1390 is under development for the treatment of glioblastoma multiforme...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RG-6237 in Facioscapulohumeral Muscular Dystrophy (FSHD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RG-6237 in Facioscapulohumeral Muscular Dystrophy (FSHD) Drug Details: RG-6237 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AZD-1390 in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AZD-1390 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: AZD-1390 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RG-6237 in Spinal Muscular Atrophy (SMA)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RG-6237 in Spinal Muscular Atrophy (SMA) Drug Details: RG-6237 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AZD-1390 in Soft Tissue Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AZD-1390 in Soft Tissue Sarcoma Drug Details: AZD-1390 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AZD-1390 in Leiomyosarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AZD-1390 in Leiomyosarcoma Drug Details: AZD-1390 is under development for the treatment of glioblastoma multiforme...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Proteinuria
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Proteinuria Drug Details: Iptacopan (LNP-023) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Paroxysmal Nocturnal Hemoglobinuria
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Paroxysmal Nocturnal Hemoglobinuria Drug Details: Iptacopan (LNP-023) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Acquired (Autoimmune) Hemolytic Anemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Acquired (Autoimmune) Hemolytic Anemia Drug Details: Iptacopan (LNP-023) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Age Related Macular Degeneration
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Age Related Macular Degeneration Drug Details: Iptacopan (LNP-023) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Glomerulonephritis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Glomerulonephritis Drug Details: Iptacopan (LNP-023) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Drug Details: Iptacopan (LNP-023) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Lupus Nephritis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Lupus Nephritis Drug Details: Iptacopan (LNP-023) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) Drug Details:...
-
Product Insights
![]()
Miami Univ – Frost Institute of Chemical and Molecular Science – Florida
Equip yourself with the essential tools needed to make informed and profitable decisions with our Miami Univ - Frost Institute of Chemical and Molecular Science - Florida report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:...
-
Product Insights
![]()
Arizona Univ – Center for Advanced Molecular and Immunological Therapies – Arizona
Equip yourself with the essential tools needed to make informed and profitable decisions with our Arizona Univ - Center for Advanced Molecular and Immunological Therapies - Arizona report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.